| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IOX2 | GDSC1000 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | -0.06 | 0.8 |
| mRNA | Nilotinib | FIMM | pan-cancer | AAC | 0.057 | 0.8 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | XMD11-85h | GDSC1000 | pan-cancer | AAC | 0.018 | 0.8 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | 0.018 | 0.8 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |